Obesity and vulnerability of the CNS  by Bruce-Keller, Annadora J. et al.
Biochimica et Biophysica Acta 1792 (2009) 395–400
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbadisReview
Obesity and vulnerability of the CNS
Annadora J. Bruce-Keller ⁎, Jeffrey N. Keller, Christopher D. Morrison
Inﬂammation and Neurodegeneration Laboratory, Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, LA 70808, USA⁎ Corresponding author. Tel.: +1 225 763 2735; fax: +
E-mail address: annadora.bruce-keller@pbrc.edu (A.
0925-4439/$ – see front matter © 2008 Elsevier B.V. A
doi:10.1016/j.bbadis.2008.10.004a b s t r a c ta r t i c l e i n f oArticle history: The incidence of obesity i
Received 18 August 2008
Received in revised form 6 October 2008
Accepted 7 October 2008
Available online 17 October 2008
Keywords:
Age
Cognition
Dementia
High fat diet
Oxidative stresss increasing worldwide, and is especially pronounced in developed western
countries. While the consequences of obesity on metabolic and cardiovascular physiology are well
established, epidemiological and experimental data are beginning to establish that the central nervous
system (CNS) may also be detrimentally affected by obesity and obesity-induced metabolic dysfunction. In
particular, data show that obesity in human populations is associated with cognitive decline and enhanced
vulnerability to brain injury, while experimental studies in animal models conﬁrm a proﬁle of heightened
vulnerability and decreased cognitive function. This review will describe ﬁndings from human and animal
studies to summarize current understanding of how obesity affects the brain. Furthermore, studies aimed at
identifying key elements of body–brain dialog will be discussed to assess how various metabolic and
adipose-related signals could adversely affect the CNS. Overall, data suggest that obesity-induced alterations
in metabolism may signiﬁcantly synergize with age to impair brain function and accelerate age-related
diseases of the nervous system. Thus, enhanced understanding of the effects of obesity and obesity-related
metabolic dysfunction on the brain are especially critical as increasing numbers of obese individuals
approach advanced age.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe epidemic of obesity has become pandemic, deﬁned as an
epidemic occurring over a wide geographic area and affecting an
exceptionally high proportion of the population. The rise in obesity
rates was ﬁrst noted in the US, but has spread to other industrialized
nations and it is even now being documented in developing countries.
Indeed, the global extent of the obesity pandemic was formally
recognized by the World Health Organization (WHO) in 1997, and
worldwide obesity rates are increasing dramatically [1]. Estimates
from the WHO indicate that as of 2005, at least 400 million adults
(9.8%) were obese. Unlike most global health concerns, the obesity
crisis is even more severe in developed nations. From 1960 to 2004,
the prevalence of obesity in the US has more than doubled among
adults from 13.3% to 32.1%, while the percentage of Americans
overweight during the same period has increased from 44.8% to 66%,
with most of this rise occurring since 1980 [2]. Obesity is clinically
identiﬁed based on measurements of body mass index [3], but can be
generally deﬁned as the physiological condition in which excess body
fat has accumulated to an extent that can negatively affect health. This
deﬁnition is based on the dramatically enhanced risk for a myriad of
disease conditions with obesity, including type 2 diabetes, cardiovas-
cular disease, gastrointestinal and respiratory difﬁculties, and many
types of cancer (reviewed in [4]). Furthermore, obesity is very closely
associated with metabolic syndrome, which is characterized by a1 225 763 0260.
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ll rights reserved.group of metabolic disorders that can include abdominal obesity,
insulin resistance or glucose intolerance, atherogenic dyslipidemia,
elevated blood pressure, and increased expression of prothrombotic
and proinﬂammatory markers (reviewed in [5]).
Based on the large body of evidence that strongly indicates that
obesity accelerates the onset and exaggerates the severity of a myriad
of age-related disorders diseases, including hypertension [6,7],
myocardial infarction [8], and stroke [9,10], one could theorize that
obesity accelerates age and age-related pathologies. Thus, it is possible
that obesity might synergistically interact with the aging process to
signiﬁcantly accelerate the development of age-related disease and
speed functional declines in large proportions of the US and global
population. The clinical signiﬁcance of this possibility is ampliﬁed by
observations that obesity rates among the elderly may be even higher
than in the general population, as estimates indicate that 72% of
Americans aged 60 and over are overweight with 32.4% obese [11].
Thus, to address this ominous potential public health crisis, it is
necessary that clinicians and investigators work together to better
understand the etiology of obesity-induced alterations to overall
health in both clinical and experimental settings.
One especially costly and debilitating deﬁcit of aging is the loss of
cognitive function and the onset of dementia. All cognitive disorders,
including dementia, become more common with age. Indeed, it has
been estimated that dementia affects as many as 6–10% of people in
industrialized nations aged 65 or older, 40–60% of whom may have
Alzheimer's disease [12–16]. Despite it's strong association with age,
dementia has been proposed as a mainly preventable conditionwith a
large number of modiﬁable risk factors, including obesity, metabolic
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overweight and 300million obese individuals worldwide [18], a better
understanding of the degree to which, and the mechanisms by which,
obesity affects the brain could not only result in signiﬁcant advances in
public health, but could also unmask the pathophysiologic processes
that might underlie age-related cognitive dysfunction and dementia.
2. Association of obesity with CNS abnormalities and dysfunction
in clinical human studies
As discussed above, the CNSmay be one of the more crucial sites at
the intersection of age and obesity. This relationship is highlighted by
observations of gross abnormalities in overall brain structure and
architecture associated with obesity. For example, regression studies
in which the effects of age and body mass index (BMI) on brain
volume and cognitionweremeasured demonstrated that both age and
increased BMI were associated with decreased brain volume [19].
Other studies have conﬁrmed alterations of brain morphology in
overweight and obese young adults, and it has been shown that
particularly in the frontal lobe, clinical obesity is associated with
reductions in focal gray matter volume and enlarged orbitofrontal
white matter [20]. Thus, these studies demonstrate that obesity in
otherwise healthy middle-aged adults is associated with axonal and/
or myelin abnormalities inwhite matter with decreases in graymatter
volumes, which could reﬂect loss of neurons. Because frontal lobe
white matter is more prone to the effects of aging than in other lobes,
these data could reﬂect accelerated aging in obese individuals.
Interestingly, these structural abnormalities may be reversible, as it
has been reported that structural changes in the brains of obese
patients may partially revert with dieting. Speciﬁcally, a recent
magnetic resonance imaging study has shown that white matter
volumes in several basal brain regions are greater in obese subjects
compared with lean subjects, with a positive correlation between
white matter volume in basal brain structures and waist to hip ratio.
More importantly, the detected white matter alterations were
partially reversed by dieting [21]. Regional gray matter volumes
(which would reﬂect neuronal cell number and/or expansion) did not
differ signiﬁcantly in obese and lean subjects, andwere not affected by
dieting [21]. However, it is important to note that these studies were
done in non-geriatric populations, indicating that while dieting may
reverse some changes, the neurobiological and functional alterations
in obese individuals that do not lose weight may be present for
decades, and it is not known if they remain reversible with advancing
age. In addition to, or possibly because of age-related structural
changes, brain aging is associated with enhanced vulnerability to and
decreased recovery from injury and/or damage. For example, aging is
associated with decreased recovery from traumatic brain injury [22],
and likewise, epidemiological data suggests that obese patients suffer
more complications and higher mortality than lean patients after
traumatic brain injury, an adverse relationship that is further
complicated by age [23]. It should be noted, however, that complete
consensus regarding the effects of obesity on traumatic injury has not
yet been achieved. Indeed, while some studies have shown that
obesity is an independent predictor of mortality following blunt
trauma [24], other studies have failed to detect increases in mortality
following traumatic injury in obese patients, although it was noted
that obese individuals had longer hospital stays compared to non-
obese patients [25]. In relation to other forms of injury, advanced age
is a major risk factor for stroke, and has been reported to increase the
severity of stroke-induced brain dysfunction [26]. Elevated adiposity
and obesity are also reported to increase the risk of stroke. For
example, epidemiological studies have revealed that obesity increases
the risk of ischemic stroke [10,27,28]. These studies are also important
in that they indicate that the increased risk for stroke in overweight or
obese subjects is independent of diabetes, hypertension, or hyperch-
olesterolemia [27]. Additionally, there is evidence indicating thatobesity not only increases stroke incidence, but also might increase
stroke-induced damage, as ischemic events in obese patients are
reported to be associated with increased complications and higher
mortality rates [29,30].
In terms of brain function, obesitymay disrupt cognition, as studies
have reported deﬁcits in learning, memory, and executive functioning
in obesewhen compared to non-obese patients [31–33]. Other studies
of young and middle-aged healthy adults have conﬁrmed the
association of obesity with behavioral declines in executive function
[34]. Overall, current evidence suggests that obesity and the
consequences of obesity, including midlife hypertension, diabetes,
and cerebrovascular disease, contribute signiﬁcantly to cognitive
decline and accelerate the development of dementia [35]. For
example, retrospective studies have found that an elevation in BMI
of only a single unit associates with a 36% increase in Alzheimer's
disease in women [36], while a prospective study of a large cohort of
people in New York City revealed that those with low-calorie or low-
fat diets had signiﬁcantly lower risks for Alzheimer's disease than did
those with higher calorie intake [37]. Similar studies have reported
that abdominal adiposity in the elderly increased the incidence of
dementia even after correcting for age [38–40]. It is important to note
that in these studies, cognitive decline was determined using
established and commonly used cognitive assessments like the mini
mental status exam, delayed word-list recall, and coding tasks.
Overall, these reports collectively indicate that obesity in humans
is associated with increases in brain injury and decreases in brain
function. These studies are important in that they underscore the
signiﬁcant public health concern that is developing as increasing
percentages of the population continue to age while carrying the
additional physiological burden of obesity. Indeed, brain injury and
dementia may be among the most costly clinical conditions to treat, as
patients are not able to work and may require institutionalization.
However, the relationship between obesity and dementia suggests
that a careful and controlled study of obesity in experimental settings
could help to unravel the pathophysiological mechanisms of age-
related dementia. Elucidation of the physiological mechanisms
whereby obesity accelerates the progression of age-related brain
dysfunction could lead to a better understanding of, and thus a better
clinicalmanagement of, unsuccessful brain aging. Thus, there has been
considerable research impetus in recent years to put well-developed
animal models of obesity to use to understand the pathogenesis of
obesity-induced CNS dysfunction.
3. Association of obesity with CNS dysfunction in experimental
animal studies
In general, animal models of obesity can be generated with
environmental manipulation (diet-induced obesity), spontaneous
mutants (ob/ob or db/db mice, fa/fa Zucker rats), genetically
engineered transgenic animals (CRF or Agrp transgenic mice) or
mechanical intervention (chemical lesion of the ventromedial
hypothalamus), and use of these animal models has contributed
strongly to the understanding of human obesity (reviewed in [41,42]).
Genetic models of obesity have been valuable for their utility in
identifying genes linked to human obesity, and for elucidating speciﬁc
pathways that regulate body weight and the pathogenesis for obesity-
related metabolic syndromes. The ob/ob leptin deﬁcient mouse gains
weight rapidly (recognizable at about 4 weeks of age) and may reach
three times the normal weight of wild type controls. In addition to
obesity and hyperphagia, mutant mice exhibit transient diabetes-like
syndrome of hyperglycemia, glucose intolerance, elevated plasma
insulin, and impaired wound healing (reviewed in [43]). Obesity in
this model is characterized by an increase in both number and size of
adipocytes, and injection of leptin into obese homozygotes sharply
reduces body weight, decreases food intake, increases energy
expenditure, and restores fertility. This speciﬁc model has been used
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be questioned whether the results obtained from genetic models of
obesity arise from the obese phenotype itself or rather the model's
genetic/pharmacological background. Thus, diet-induced models of
obesity are thought by some to better model obesity in humans,
particularly in Western industrialized nations in which high fat/high
calorie diets are commonplace. Studies in which specially formulated
high fat or calorie diets were given to experimental animals revealed
that such diets promote obesity, hyperglycemia, whole-body insulin
resistance, and generalized metabolic syndrome function [41,46,47].
Indeed, dietarymanipulation studies in experimental animals have led
to important advances in the ﬁeld, including a better understanding of
the relative health beneﬁts of ﬁsh-based versus animal-based fats [47].
However, an important downside to this approach is the variability in
deﬁnition of the term “dietary manipulation”. Indeed, while numerous
investigators have used this approach, neither the exact content nor
composition of the diets employed is standardized. For example, while
some investigators employ well-deﬁned, commercially available high fat
diets in which the fat component replaces carbohydrate and/or protein
components, others have simply added fat to a standard rodent chow,
leading to an unbalanced diet composition with respect to nutrient
content [47]. Unfortunately, then, various diets with very different fat
and/or calorie compositions are summarized under the term “diet-
induced obesity” in the literature. While diet-induced models of obesity
may thus be better experimental representations of obesity in humans,
the wide variation in available diets precludes easy comparisons across
studies using different diet formulations. However, observations that
remain consistent across both genetic and different diet-inducedmodels
of obesity likely highlight a common physiological process that is also
likely to accordingly transcend species differences to participate in the
human condition, and several excellent reviews are available that
systematically describe the currently available animal models of obesity
[41,43,47–49].
Oneof the earliest reports of adverse effects of experimental obesityon
brainpathology described alterations to the lipid composition ofmyelin in
genetically obese mice. While dysfunction of peripheral myelin and
sensory neuropathy is a well established characteristic of type 2 diabetes
[50,51], this study reported that genetically obese (ob/ob) mice had
decreased overall levels of myelin andmarked alterations to the fatty acid
compositionof themyelin as compared towild typemice [52]. Theuseof a
genetic model for these studies is signiﬁcant in that it suggests that
increased adiposity, rather than increase in dietary lipids, is sufﬁcient to
alter the composition of brain myelin. This study is supported by more
recent imaging studies inhumans thatalsohave revealedchanges inwhite
matter and myelin abnormalities in association with obesity [53,54].
While the human studies have not been followed up by pathology studies
to characterize the actual molecular and biochemical changes to human
myelin in obese patients, an obvious consequence of altered myelination
would be altered synaptic transmission, and indeed, animal studies have
conﬁrmed that experimental obesity is associated with a wide array of
cognitive abnormalities [55,56]. For example, diet-induced obesity and
insulin resistance have both been shown by several groups to decrease
spatial learning skills in rats [57–59]. Other studies have likewise shown
that diet-induced obesity is able to synergize with traumatic brain injury
in decreasing hippocampal plasticity and learning [60]. Studies have also
examined biochemical and histological indices of synaptic dysfunction
and reported that obesity is associated with decreases in dendritic spine
density [57] and in the expression of synaptic marker proteins such as
synapsin and GAP-43 [59–61]. Interestingly, these studies of synaptic
markers also reported decreases in local levels of the neurotrophic factor
BDNF, suggesting that brain regulation of growth factor synthesis could be
regulated byobesity and/ormetabolic syndromes. As it iswell established
that BDNF supports synaptic plasticity and neuronal excitability [62], and
appears to be important for maintaining learning and memory function,
particularly in aging [63–65], these studies again support the hypothesis
that obesity is able to accelerate the physiological indices of brain aging.Studies have also documented that experimental obesity can
synergize with other pathophysiological conditions related to brain
aging. For instance, obesity-induced by a high calorie diet has been
shown to increase insoluble amyloid burden and decrease cognitive
performance in a transgenic mouse model of Alzheimer's disease [66].
Complementary studies have also demonstrated that the obesity-
related peptide leptin (see Section 4 below) is able to regulate the
secretion and uptake of amyloid beta peptides in vitro [67]. In relation
to stroke, studies have shown that blood–brain barrier dysfunction
and infarct volume following middle cerebral artery occlusion is
increased in genetically obese mice compared to non-obese wild type
mice [45]. Finally, it has also been established that neurodegeneration
induced by speciﬁc neurotoxins is increased by both genetic [68] and
diet-induced obesity [69].
Although the physiologic mechanisms whereby obesity adversely
affects the brain are not understood (see Section 4, below), both
experimental and human studies have shown that obesity is
associated with increased oxidative stress, which has been implicated
in cognitive declines seen in neurodegenerative diseases [70,71], and
indeed has been suggested to be altered by diet [72]. For example,
several studies have shown that administration of high fat or high
calorie diets to rodents increases free radical generation [73] and
protein oxidation [74] in the brain. Furthermore, it has been shown in
the Zucker genetic model of rat obesity that endothelial cell
dysfunction in this model is caused by oxidative stress secondary to
overactivation of NADPH oxidase, which in turn is caused by
circulating free fatty acids [75]. Interestingly, NADPH oxidase has
also been shown in human studies to mediate obesity-induced
oxidative stress in both blood mononuclear cells [76] and endothelial
cells [77]. Finally, it should be noted that it has been demonstrated
that administration of the lipid-soluble antioxidant Vitamin E not only
reverses oxidative modiﬁcation to proteins in the brains of rats given a
high-fat diet, but also normalizes levels of BDNF, synapsin I and cyclic
AMP-response element-binding protein (CREB), and prevents obe-
sity-induced alterations to cognitive function [61]. It should be noted,
however, that it is not clear at this point if oxidative stress in genetic or
diet-induced animal models of obesity are a result of obesity per se, or
more related to obesity-related metabolic syndrome. Thus, available
data from animal models indicates that obesity and/or metabolic
syndrome can induce neuropathology and cognitive dysfunction and
can also synergizewith pathological conditions and/or environmental
toxins to accelerate CNS dysfunction. Thus, investigation into the
dialog of peripheral signals of adiposity with the CNS is necessary to
dissect out the mechanisms of obesity-induced brain pathology.
4. Potential mediators of obesity-related CNS dysfunction
The mechanism(s) by which obesity results in brain injury and/or
dysfunction are uncertain and subject to extensive speculation. While
postulated indirect mechanisms include the effects of hyperglycemia
on brain energetics and/or vascular damage to the central nervous
system [78], it is well known that consumption of a high fat diet and/
or increased adiposity causes dramatic changes in the proﬁle of
bioactive serum lipids, including cholesterol. While an association
between cholesterol and cognitive function could be explained based
on increased risk stroke or cerebrovascular hypoperfusion, many
studies have examined the role of serum cholesterol in brain function
independent of vascular effects. In general, results are mixed, with
some studies noting a correlation between lipid levels and cognitive
function, whereas other studies do not [79–81]. Positive studies
related to the role of cholesterol in dementia have primarily related to
effects of statin drug use, but these studies have also yielded mixed
results, with a generally diminished risk for dementia although some
of the tests did not achieve statistical signiﬁcance [82].
Interestingly, there is compelling evidence that triglycerides and/or
free fatty acids might mediate CNS alterations in obese individuals. In
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obesity as other lipid mediators, particularly cholesterol, are subject to
complex genetic control. Recent studies have indeed highlighted a
potentially important role for triglycerides in the cognitive and
pathological alterations in obesity. For example, it has been shown
that direct administration of triglycerides can impair hippocampal long-
term potentiation, and that lowering of triglycerides pharmacologically
with gemﬁbrozil reduces the expressionofmarkers of oxidative stress in
the brains of obese mice [83]. These studies are further supported by
clinical studies inwhich it has beenshown thatelevated triglycerides are
associated with poor cognitive performance in patients with type 2
diabetes [84], and by studies in which the reduction of hypertriglycer-
idemia with gemﬁbrozil improved cerebral blood ﬂow and function on
the cognitive capacity screening examination [80]. Finally, triglycerides
have been shown to impair leptin transport through the blood–brain
barrier [85], indicating that thewell-characterized phenomena of leptin
resistance may be related in part to the action of triglycerides at the
blood–brain barrier. Another potential means whereby triglycerides
could adversely affect the brain is through their breakdown into free
fatty acids, which can also be formed and released directly from
adipocytes. Indeed, there is abundant evidence that alterations in free
fatty acid metabolism play a key role in many of the local and systemic
manifestations of obesity, including insulin resistance, pancreatic beta
cell injury, and dyslipidemia [86–88]. In speciﬁc relation to the brain,
GPR40, a putative free fatty acid receptor, has been localized to the
hippocampus [89], and the saturated free fatty acids palmitic acid and
lauric acid have both been shown to cause inﬂammatory signaling in
cultured macrophages [90,91], and also to modulate astrocytic and
microglial signaling [92]. Conversely, oleic acid has been shown to be
ineffective at inducing an inﬂammatory phenotype in immunocompe-
tent cells [90]. Finally, circulating glucocorticoids have also been studied
in terms of their ability to perturb brain function in models of obesity.
Obesity is strongly associated with elevated circulating endogenous
glucocorticoids, possibly through chronic activation of the sympathetic
nervous system [93], and a recent series of elegant studies has provided
evidence that elevated glucocorticoids could mediate the effects of
diabetes on hippocampal neurogenesis, synaptic plasticity, and cogni-
tive performance [94,95].
In addition to bioactive lipids, serum factors related to adiposity
could adversely affect the brain. Indeed, adipose tissue is no longer
considered to be an inert tissue functioning solely as an energy store,
but is emerging as an important factor in the regulation of many
pathological processes [96,97]. Numerous secreted products of
adipose tissue have been identiﬁed and characterized, and given the
moniker “adipokines”. Over 50 adipokines have been identiﬁed, and
generally function as hormones to inﬂuence energy homeostasis and
feeding behavior [98]. Furthermore, some adipokines, particularly
adiponectin and leptin may provide an important link between
obesity, insulin resistance and related inﬂammatory disorders
[99,100]. Leptin, originally identiﬁed in 1994 as the 16 kDa product
of the ob gene [101] may also be important in CNS responses to
obesity. Leptin is best known for its action as an afferent adiposity
signal to the brain that suppresses appetite and increases energy
expenditure [102]. Leptin enters the brain via a saturable transport
mechanism [103] and while it is known that leptin acts on
hypothalamic centers to regulate feeding behavior, leptin receptors
(OBR) are widely expressed in numerous extra-hypothalamic regions
of the brain, including the hippocampus, cerebellum, amygdale, and
brain stem [104–106]. While the full extant of leptin's actions on the
brain have not been characterized, the past decade of research has not
only revealed that leptin receptors are widely expressed in the CNS,
but has also identiﬁed numerous additional functions for this
hormone in the brain [107]. In particular, there is evidence that leptin
inﬂuences neuronal excitability via the activation and trafﬁcking of
potassium channels in several brain regions, which may be important
in regulation of food intake, cognition, and also anti-convulsant effects[108]. A number of studies have also identiﬁed a role for leptin in
cognitive processes [109]. For example, it has been shown that direct
administration of leptin into the dentate gyrus enhances long-term
potentiation [110], and that intravenous administration of leptin to
rats facilitates behavioral performance in passive avoidance and
Morris water-maze tasks [111]. Finally, leptin has been shown to
modulate the inﬂammatory signaling in microglia [112,113] which
could affect brain inﬂammatory and oxidative pathways.
As a ﬁnal note, there is a body of data that suggests a potential
scenario whereby the sensory perception (generally via olfaction or
taste) of calories or nutrients might signiﬁcantly inﬂuence the activity
of metabolic hormones and modulate lifespan [114,115]. For example,
studies in both Drosophila melanogaster and Caenorhabditis elegans
have shown that genetic mutations that cause defects in sensory cilia
or their support cells, or in sensory signal transduction, signiﬁcantly
extend lifespan [116,117]. Furthermore, exposure of Drosophila to
food-derived odorants has been shown to partially reverse the
longevity-extending effects of dietary restriction [117]. While the
mechanisms whereby sensory perception regulates lifespan is not
entirely clear, effects on insulin/IGF (insulin-like growth factor)
signaling are thought to be involved [118]. Overall, these data indicate
that a perceived lack of nutritional resources (via defects in olfaction)
can increase lifespan via a physiologic stress response similar to
caloric restriction [115]. It should be noted that the converse – the
perception of adequate or excess resources via exposure to food-
related odorants – does not appear to decrease lifespan in animals that
are not calorically restricted [117]. However, other studies have
indicated that gustatory perception can be sufﬁcient to modulate
plasma insulin and glucose turnover, as saccharin was shown to
induce cephalic-phase insulin release, and to increase hepatic glucose
production in rats [119]. Thus, the potential exists for modulation of
longevity and metabolism via environmental sensing, although the
degree to which this potential scenario might participate in the
physiologic complications of obesity in humans is not at all resolved.
5. Conclusions and unanswered questions
It is now very clear that nutrition, as an integral component of
human physiology, has the ability to modulate cognitive function and
CNS responses to injury. There is a great concern therefore, to critically
evaluate and understand the mechanisms by which nutrition and
particularly obesity can affect neuroplasticity and cognitive function. As
summarized in this review, there is compelling evidence that obesity
modulates brain responses, andmay in particular accelerate brain aging
and age-related neurodegeneration. While it is not currently known
howobesity disrupts brain homeostasis during aging, numerous clinical
and rodent studies strongly link diet-inducedmetabolic disturbances to
the development of dementia. The progressive nature by which diet-
induced obesity promotes brain disturbances raises the possibility that
the careful implementation and study of this model will lead to better
understanding of the linkages between metabolism and the brain, and
might also unravel the complex relationship betweenbrain function and
measurable aspects of brainpathology. An additional key issue to resolve
relates to the role of maternal obesity in the cognitive strength and
health of offspring and the further predisposition of the offspring to
obesity and/or enhanced CNS responses to obesity.References
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